Quantum News
Sign InSign Up
Back to News
research

Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Crinetics Pharmaceuticals reported Q4 2025 earnings on February 26, 2026, highlighting strong financial growth with full-year revenue reaching $125 million, up 40% year-over-year. CEO Scott Struthers emphasized progress in their lead drug, paltusotine, for acromegaly and carcinoid syndrome, noting Phase 3 trial success and planned 2026 FDA submission. CFO Tobin Schilke outlined a $200 million cash runway extending into 2027, supporting R&D expansion and commercialization efforts. Chief Endocrinologist Alan Krasner detailed positive Phase 2 data for CRN04894 in congenital hyperinsulinism, targeting pediatric approvals by 2028. Analysts questioned commercialization strategies and pipeline timelines, with management reaffirming confidence in their rare endocrine disease portfolio’s long-term potential.
AI Audio Summary
0:00 / 0:00
Click to play
Untitled design (26).png
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts158.67K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call February 26, 2026 4:30 PM EST Company Participants Gayathri Diwakar - Senior Director of Investor RelationsR. Struthers - Founder, President, CEO & DirectorAlan Krasner - Chief EndocrinologistTobin Schilke - Chief Financial OfficerIsabel Kalofonos - Chief Commercial Officer Conference Call Participants Maxwell Skor - Morgan Stanley, Research DivisionYasmeen Rahimi - Piper Sandler & Co., Research DivisionAlexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research DivisionTyler Van Buren - TD Cowen, Research DivisionYesha Patel - Evercore ISI Institutional Equities, Research DivisionLuke Junk - Robert W. Baird & Co. Incorporated, Research DivisionJoseph Schwartz - Leerink Partners LLC, Research DivisionJonathan Wolleben - Citizens JMP Securities, LLC, Research DivisionKatherine Kaiser-Dellorusso - LifeSci Capital, LLC, Research DivisionYuchen Ding - Jefferies LLC, Research DivisionCatherine Novack - JonesTrading Institutional Services, LLC, Research DivisionDouglas Tsao - H.C. Wainwright & Co, LLC, Research DivisionAndy Chen - Wolfe Research, LLC Presentation Operator Welcome to Crinetics Pharmaceuticals Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] I would now like to turn the call over to Gayathri Diwakar, Head of Investor Relations. Please go ahead. Gayathri DiwakarSenior Director of Investor Relations Thank you, operator. Good afternoon, everyone, and thank you for joining us to discuss the fourth quarter and full year 2025 results. Today on the call, we have Dr. Scott Struthers, Founder and Chief Executive Officer; Dr. Alan Krasner, Chief Endocrinologist; and Tobin Schilke, Chief Financial Officer. Also joining for the Q&A portion will be Isabel Kalofonos, Chief Commercial Officer. Please note, there's a slide deck for today's presentation, which is in the Events and Presentations section of the Investors page on the Crinetics website. In addition, a press release was issued earlier today and is also available on the corporate website. As a reminder, we'll be making

Read Original

Tags

drug-discovery

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.